Malignant Splenic Neoplasm

cancer family

Identifier: CI-CAN-00000255
Entity page: /cancer/malignant-splenic-neoplasm ↗
Edges: 244

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Splenic Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 74show all (up to 200)
→ investigated in trials for	Rituximabmonoclonal antibody 33 trials (4 active) · roll-up of the cancer and its descendants	—	—	Malignant Splenic Neoplasm	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule

Malignant Splenic Neoplasm studied in …STUDIED_INderived10 of 170show all (up to 200)
→ studied in	NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 170 trials mapped (24 active)	—	—	Splenic Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04815356Phase 1 · recruiting Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant · condition mapped ONTOLOGY_EXACT · 170 trials mapped (24 active)	—	—	Hairy Cell Leukemia Variant	1	Observed	clinicaltrials	graph →
→ studied in	NCT01841723Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia · condition mapped ONTOLOGY_EXACT · 170 trials mapped (24 active)	—	—	Hairy Cell Leukemia Variant	1	Observed	clinicaltrials	graph →
→ studied in	NCT06311227Phase 2 · active not recruiting Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia · condition mapped CURATED_BROADER · 170 trials mapped (24 active)	—	—	Hairy Cell Leukemia Variant	1	Observed	clinicaltrials	graph →
→ studied in	NCT07055477Phase 1 · recruiting A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) · condition mapped ONTOLOGY_EXACT · 170 trials mapped (24 active)	—	—	Hepatosplenic T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 170 trials mapped (24 active)	—	—	Hepatosplenic T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped CURATED_BROADER · 170 trials mapped (24 active)	—	—	Splenic Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07759661not yet recruiting Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies · condition mapped ONTOLOGY_EXACT · 170 trials mapped (24 active)	—	—	Splenic Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 170 trials mapped (24 active)	—	—	Splenic Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05735834Phase 3 · active not recruiting Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients · condition mapped ONTOLOGY_EXACT · 170 trials mapped (24 active)	—	—	Splenic Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains